noscript

News and Announcements

Dr Antony Rapisarda of OrthoDx™

  • Published December 06, 2022 6:56AM UTC
  • Publisher Maan Perez
  • Categories CEO Interviews

OrthoDx™ is a privately held company based out of Sydney, Australia, focused on the development and commercialization of novel genomic biomarkers for use in the diagnosis of joint pain. The primary function of the first genomic signature for clinical use is to aid surgeons and physicians to differentiate between infection-negative and infection-positive synovial joint inflammation in adults. 

Watch this interview with CEO Dr. Antony Rapisarda as he discusses SynvIchor™, their biomarker technology and the company’s current and future milestones.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now